Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Last trade$3.80
Day change-$0.01 (-0.26%)
Day range$3.78 – $4.07
Volume417,639
Market cap$230M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$230.39M
Price / earnings
—
Price / book
1.15×
Price / sales
1×
EV / sales
0.74×
EV / EBITDA
-1.01×
Profitability
Earnings per share
-$4.54
Return on assets
-71.88%
Return on equity
-137.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
1.54×
Quick ratio
1.53×
Cash ratio
0.4×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$139.96M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VNDA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$69.82M
$50.53M
$51.72M
$57.22M
$56.26M
$52.59M
$50.04M
$53.19M
Cost of revenue
$4.15M
$3.56M
$3.16M
$3.83M
$2.95M
$2.74M
$3.52M
$2.59M
Gross profit
$65.66M
$46.97M
$48.56M
$53.38M
$53.3M
$49.85M
$46.52M
$50.6M
Selling, general and administrative
$59.58M
$71.84M
$68.36M
$62.98M
$60.27M
$64.62M
$50.08M
$39.28M
Research and development
$27.62M
$36.95M
$28.44M
$29.01M
$22.56M
$21.99M
$35.71M
$19.84M
Total operating expenses
$89.18M
$110.78M
$98.78M
$93.74M
$84.59M
$88.36M
$87.55M
$60.87M
Operating income
-$23.52M
-$63.81M
-$50.22M
-$40.35M
-$31.28M
-$38.5M
-$41.03M
-$10.28M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$22.39M
-$62.38M
-$48.42M
-$38M
-$28.39M
-$34.89M
-$37.37M
-$6.5M
Income taxes
$174K
$129K
$143K
$103.19M
-$5.8M
-$7.68M
-$7.87M
-$1.59M
Net income
-$22.56M
-$62.51M
-$48.57M
-$141.19M
-$22.59M
-$27.21M
-$29.49M
-$4.91M
Net income attributable to common shareholders
-$22.56M
-$62.51M
-$48.57M
-$141.19M
-$22.59M
-$27.21M
-$29.49M
-$4.91M
EBITDA
-$21.29M
-$61.56M
-$47.96M
-$38.3M
-$29.23M
-$36.49M
-$39.05M
-$8.31M
Basic earnings per share
-$0.37
-$1.04
-$0.82
-$2.39
-$0.38
-$0.46
-$0.50
-$0.08
Diluted earnings per share
-$0.37
-$1.04
-$0.82
-$2.39
-$0.38
-$0.46
-$0.50
-$0.08
Recent news
Company coverage with links to the original publishers.
Fortrea Holdings Inc. (FTRE) is expected to report Q3 2026 earnings of $0.24 per share, representing 100% year-over-year growth, though revenues are projected to decline 4.4%. With a negative Earnings ESP of -10.35% and Zacks Rank #3 (Hold), the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in 2 of the last 4 quarters.
Xenon Pharmaceuticals paused enrollment in phase III depression trials for azetukalner after unexpected neurological and psychiatric side effects emerged, including confusion, speech difficulties, and psychosis cases. The company is reviewing dose adjustments with top-line results expected in Q1 2027. However, Xenon's epilepsy program remains promising, with an FDA application pending for focal onset seizures treatment, offering potential growth opportunities despite the depression program setback.
U.S. stock futures declined on New Year's Eve as hopes for a year-end Santa Claus rally fade. Markets remain jittery following President Trump's threats against Federal Reserve Chair Jerome Powell. Investors await the Initial Jobless Claims report before market open. The S&P 500, Dow Jones, and Nasdaq 100 all traded lower in premarket, with several individual stocks showing significant moves based on company announcements and FDA approvals.
The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.
Vanda Pharmaceuticals reported a Q2 2025 net loss of $27.2 million, with revenue rising 4% to $52.6 million. Fanapt® showed strong sales growth, while HETLIOZ® and PONVORY® experienced declines. The company continues to invest in its product pipeline and expand market reach.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.